Bellicum Pharmaceuticals (BLCM) Upgraded to Sell by BidaskClub

BidaskClub upgraded shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) from a strong sell rating to a sell rating in a report published on Thursday.

Several other brokerages also recently weighed in on BLCM. ValuEngine upgraded Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a research note on Monday, September 18th. Jefferies Group reiterated a buy rating and issued a $16.00 target price on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. Raymond James Financial reiterated a buy rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, December 12th. Finally, Zacks Investment Research upgraded Bellicum Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of $26.20.

Bellicum Pharmaceuticals (BLCM) traded down $0.29 on Thursday, reaching $9.50. The company’s stock had a trading volume of 442,000 shares, compared to its average volume of 573,033. The firm has a market capitalization of $312.99, a price-to-earnings ratio of -3.18 and a beta of 1.18. Bellicum Pharmaceuticals has a 52 week low of $7.41 and a 52 week high of $15.55. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.03. The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.03 million. The company’s quarterly revenue was up 18.2% on a year-over-year basis. During the same period last year, the firm earned ($0.66) EPS. sell-side analysts predict that Bellicum Pharmaceuticals will post -2.93 earnings per share for the current fiscal year.

In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 17,117 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $9.33, for a total value of $159,701.61. Following the transaction, the chief financial officer now directly owns 31,585 shares in the company, valued at approximately $294,688.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alan A. Musso sold 6,206 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $9.89, for a total value of $61,377.34. The disclosure for this sale can be found here. Company insiders own 18.77% of the company’s stock.

Several hedge funds have recently made changes to their positions in BLCM. Cubist Systematic Strategies LLC purchased a new stake in shares of Bellicum Pharmaceuticals in the third quarter valued at approximately $164,000. Point72 Asset Management L.P. purchased a new stake in shares of Bellicum Pharmaceuticals in the third quarter valued at approximately $4,723,000. Schwab Charles Investment Management Inc. boosted its stake in shares of Bellicum Pharmaceuticals by 47.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock valued at $1,516,000 after buying an additional 41,995 shares in the last quarter. Harvey Capital Management Inc. purchased a new stake in shares of Bellicum Pharmaceuticals in the third quarter valued at approximately $458,000. Finally, D.A. Davidson & CO. boosted its stake in shares of Bellicum Pharmaceuticals by 17.4% in the third quarter. D.A. Davidson & CO. now owns 47,650 shares of the biopharmaceutical company’s stock valued at $550,000 after buying an additional 7,050 shares in the last quarter. Institutional investors own 55.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Bellicum Pharmaceuticals (BLCM) Upgraded to Sell by BidaskClub” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/01/05/bellicum-pharmaceuticals-blcm-upgraded-to-sell-by-bidaskclub.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply